How PD-L1 Biomarker Test Results Impact Clinical Management of Lung CancerVideo Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Drs. Goeffrey Oxnard and Lauren Ritterhouse review how the results of PD-L1 testing influence the choices in first- or second-line immunotherapy or combination immunochemotherapy in patients with squamous or non-squamous non-small-cell lung cancer.
Dixie-Lee Esseltine, MD and George Mulligan, PhD discuss the challenges in the current standards of care of patients with multiple myeloma in the relapse setting.
Grant Lawless discusses the definition of value in personalized medicine from different perspectives